title: m-AMSA in epithelial carcinoma of the ovary. A Southwest Oncology Group study.
abstract: Twenty-three patients with advanced heavily pretreated epithelial carcinoma of the ovary were treated with m-AMSA. Eleven patients received a mean of 2.3 courses at a dose of 40 mg/m2 X 3 days q 21 days and 12 patients received a mean of 4.3 courses at a dose of 30 mg/m2 X 3 days q 21 days intravenously. One (5%) partial response in 22 fully evaluable patients was observed. Toxicity was mild and well tolerated. We conclude that m-AMSA is a relatively inactive drug in the treatment of epithelial ovarian carcinoma.
mesh_terms: D000609:Aminoacridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000677:Amsacrine; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*
chemical_list: D000609:Aminoacridines; D000970:Antineoplastic Agents; D000677:Amsacrine